Immunovant, Inc.

NasdaqGS:IMVT Stock Report

Market Cap: US$5.4b

Immunovant Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:IMVT Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
21 Jan 26SellUS$51,461Jay StoutIndividual1,977US$26.03
07 Jan 26SellUS$31,914Jay StoutIndividual1,203US$26.92
18 Dec 25SellUS$290,943Christopher Van TuylIndividual10,813US$27.38
12 Dec 25BuyUS$349,999,986Roivant Sciences Ltd.Company16,666,666US$21.00
20 Nov 25SellUS$298,237Melanie GloriaIndividual12,626US$23.97
22 Oct 25SellUS$47,956Jay StoutIndividual2,520US$19.03
22 Oct 25SellUS$49,383Michael GeffnerIndividual2,595US$19.03
08 Oct 25SellUS$25,836Jay StoutIndividual1,585US$16.30
08 Oct 25SellUS$20,734Michael GeffnerIndividual1,272US$16.30
23 Jul 25SellUS$43,288Michael GeffnerIndividual2,385US$18.15
23 Jul 25SellUS$50,911Jay StoutIndividual2,805US$18.15
09 Jul 25SellUS$26,188Jay StoutIndividual1,519US$17.24
09 Jul 25SellUS$19,998Michael GeffnerIndividual1,160US$17.24
23 Apr 25SellUS$34,742Michael GeffnerIndividual2,349US$14.79
23 Apr 25SellUS$28,471Jay StoutIndividual1,925US$14.79
16 Apr 25SellUS$44,566Eva BarnettIndividual2,993US$14.89
16 Apr 25SellUS$123,900Peter SalzmannIndividual8,321US$14.89
09 Apr 25SellUS$364,941Peter SalzmannIndividual28,094US$12.99
09 Apr 25SellUS$80,135Michael GeffnerIndividual6,169US$12.99
09 Apr 25SellUS$143,708Eva BarnettIndividual11,063US$12.99
09 Apr 25SellUS$65,002Jay StoutIndividual5,004US$12.99

Insider Trading Volume

Insider Buying: IMVT insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of IMVT?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders1,197,6610.537%
VC/PE Firms11,526,9715.17%
Institutions97,030,09243.5%
Public Companies113,317,00750.8%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.8%.

Top Shareholders

Top 25 shareholders own 101.9% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
55.7%
Roivant Sciences Ltd.
113,317,007US$3.0b17.2%no data
8.34%
FMR LLC
16,979,123US$451.6m15.4%0.02%
5.66%
Deep Track Capital, LP
11,526,971US$306.6m18.5%6.38%
3.82%
The Vanguard Group, Inc.
7,779,314US$206.9m13.9%no data
2.98%
BlackRock, Inc.
6,058,170US$161.1m5.58%no data
2.93%
T. Rowe Price Group, Inc.
5,953,455US$158.4m10.9%0.01%
2.82%
Armistice Capital LLC
5,747,155US$152.9m-1.52%3.65%
2.68%
Baker Bros. Advisors LP
5,457,881US$145.2m0%0.76%
1.86%
State Street Global Advisors, Inc.
3,786,926US$100.7m30.9%no data
1.57%
Morgan Stanley Investment Management Inc.
3,199,245US$85.1m412%0.07%
1.56%
RTW Investments, LP
3,177,850US$84.5m0%0.89%
1.41%
Two Seas Capital LP
2,866,962US$76.3m3.8%3.92%
1.29%
Alpine Global Management, LLC
2,627,692US$69.9m-4.61%13.83%
1.22%
ADAR1 Capital Management, LLC
2,480,968US$66.0m10.7%4.91%
0.98%
Point72 Asset Management, L.P.
2,000,000US$53.2m-46.5%0.08%
0.98%
Perceptive Advisors LLC
1,994,890US$53.1m25.6%0.98%
0.97%
Woodline Partners LP
1,975,869US$52.6m31.8%0.2%
0.91%
Geode Capital Management, LLC
1,857,532US$49.4m3.1%no data
0.82%
TCG Crossover Management, LLC
1,660,933US$44.2m0%1.33%
0.68%
Morgan Stanley
1,382,098US$36.8m28.7%no data
0.68%
Logos Global Management, L.P.
1,375,000US$36.6m400%2.25%
0.58%
Aberdeen Group Plc
1,184,122US$31.5m20.6%0.01%
0.55%
Soleus Capital Management, L.P.
1,110,000US$29.5m0%1.2%
0.51%
The Goldman Sachs Group, Inc.
1,031,346US$27.4m-0.05%0.01%
0.43%
UBS Asset Management AG
866,827US$23.1m4.01%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/23 20:22
End of Day Share Price 2026/02/20 00:00
Earnings2025/12/31
Annual Earnings2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Immunovant, Inc. is covered by 24 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Jason Matthew GerberryBofA Global Research
Dina RamadaneBofA Global Research